Structured evidence table for Palmitoylethanolamide Joint Comfort Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Palmitoylethanolamide Joint Comfort Randomized Trial | Depending on disease severity, eczema is associated with several comorbid chronic health disorders, impaired quality of life, and increased healthcare dependence []. | 2 | Rao Amanda (2024) | Efficacy of Topical Palmitoylethanolamide (Levagen+) for the Management of Eczema Symptoms: A Double-Blind, Comparator-Controlled, Randomized Clinical Trial |
| Palmitoylethanolamide Joint Comfort Randomized Trial | The complexity and numerous factors associated with eczema have made the development of therapies targeted at eczema management and relief difficult. | 2 | Rao Amanda (2024) | Efficacy of Topical Palmitoylethanolamide (Levagen+) for the Management of Eczema Symptoms: A Double-Blind, Comparator-Controlled, Randomized Clinical Trial |
| Palmitoylethanolamide Joint Comfort Randomized Trial | In the lesional skin, mast cells interact with the nerve fibres by releasing allogenic and puritogenic mediators that result in the release of inflammatory neuropeptides thus, creating a vicious negative feedback loop []. | 2 | Rao Amanda (2024) | Efficacy of Topical Palmitoylethanolamide (Levagen+) for the Management of Eczema Symptoms: A Double-Blind, Comparator-Controlled, Randomized Clinical Trial |
| Palmitoylethanolamide Joint Comfort Randomized Trial | 1 2 3 4 5 Eczema (atopic dermatitis) is a chronic, multifactorial inflammatory skin disease characterised by itchy, dry, rough, and scaling skin []. | 2 | Rao Amanda (2024) | Efficacy of Topical Palmitoylethanolamide (Levagen+) for the Management of Eczema Symptoms: A Double-Blind, Comparator-Controlled, Randomized Clinical Trial |
Source documents